Rockefeller Capital Management’s Blueprint Medicines BPMC Stock Holding History

Rockefeller Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28	Closed	-$1K	–	2217
2022 Q4	$1K	Hold	28	–	–	﹤0.01%	3645
2022 Q3	$1K	Sell	28 -26	-48%	-$1.67K	﹤0.01%	3674
2022 Q2	$2K	Sell	54 -12	-18%	-$703	﹤0.01%	3753
2022 Q1	$4K	Sell	66 -171	-72%	-$12.3K	﹤0.01%	3389
2021 Q4	$25K	Sell	237 -266	-53%	-$27.8K	﹤0.01%	2525
2021 Q3	$51K	Buy	503 +488	+3,253%	+$45.4K	﹤0.01%	2128
2021 Q2	$1K	Buy	+15	New	+$1.37K	﹤0.01%	3311
2019 Q4	–	Sell	-786	Closed	-$58K	–	2055
2019 Q3	$58K	Sell	786 -12	-2%	-$1.04K	﹤0.01%	920
2019 Q2	$75K	Buy	798 +781	+4,594%	+$64.5K	﹤0.01%	744
2019 Q1	$1K	Buy	+17	New	+$1.26K	﹤0.01%	1841

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rockefeller Capital Management's BPMC Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Blueprint Medicines (BPMC) in Q1 2023, closing a stake of 28 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in BPMC in Q1 2019 and held it in 10 quarters. The position peaked at $75K in Q2 2019. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2023.

Rockefeller Capital Management reported no remaining Blueprint Medicines position as of Q1 2023 after selling out during the quarter.
Rockefeller Capital Management sold 28 Blueprint Medicines shares in Q1 2023, an estimated $1K.
Rockefeller Capital Management first reported a position in Blueprint Medicines in Q1 2019 and held it in 10 quarters.
Rockefeller Capital Management's Blueprint Medicines position peaked at $75K in Q2 2019.
214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.